Callan Family Office LLC Invests $14.78 Million in AbbVie Inc. $ABBV

Key Points

• Callan Family Office LLC acquired 58,732 AbbVie shares worth approximately $14.78 million during the second quarter. Institutional investors collectively own 70.23% of AbbVie.
• AbbVie’s latest quarterly results exceeded expectations, with adjusted EPS of $3.65 and revenue of $16.99 billion, up 10.2% year over year. The company guided for third-quarter 2026 EPS of $3.84–$3.88.
• Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and an average price target of $275.95 versus the stock’s reported $259.87 price. AbbVie also pays a quarterly dividend of $1.73 per share, representing a 2.7% yield.

Callan Family Office LLC bought a new position in AbbVie Inc. (NYSE:ABBV - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 58,732 shares of the company's stock, valued at approximately $14,779,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Litman Gregory Wealth Management LLC purchased a new position in shares of AbbVie in the 4th quarter worth about $28,000. Imprint Wealth LLC lifted its stake in shares of AbbVie by 56.2% in the 4th quarter. Imprint Wealth LLC now owns 125 shares of the company's stock valued at $29,000 after purchasing an additional 45 shares in the last quarter. Legacy Wealth Managment LLC ID grew its holdings in shares of AbbVie by 115.9% during the 4th quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company's stock worth $31,000 after purchasing an additional 73 shares during the period. IFC & Insurance Marketing Inc. acquired a new stake in AbbVie during the 4th quarter worth approximately $31,000. Finally, Abound Financial LLC purchased a new position in AbbVie in the fourth quarter valued at approximately $32,000. Institutional investors and hedge funds own 70.23% of the company's stock.

AbbVie Price Performance

Shares of ABBV stock opened at $259.87 on Wednesday. The company's fifty day moving average price is $253.69 and its two-hundred day moving average price is $229.43. The firm has a market capitalization of $459.14 billion, a P/E ratio of 73.41, a P/E/G ratio of 1.16 and a beta of 0.29. AbbVie Inc. has a 12 month low of $190.75 and a 12 month high of $267.47.

AbbVie (NYSE:ABBV - Get Free Report) last announced its earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, beating the consensus estimate of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The company had revenue of $16.99 billion during the quarter, compared to the consensus estimate of $16.80 billion. During the same period last year, the firm earned $2.97 earnings per share. The company's revenue was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, sell-side analysts anticipate that AbbVie Inc. will post 14.05 EPS for the current year.

AbbVie Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th were issued a dividend of $1.73 per share. The ex-dividend date was Wednesday, July 15th. This represents a $6.92 annualized dividend and a yield of 2.7%. AbbVie's payout ratio is currently 195.48%.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Allergan Aesthetics, an AbbVie company, launched SkinMedica Barrier Calming Cream and introduced HA 5 Hydra Collagen Facial Mist. Clinical testing reportedly showed a 30% reduction in skin dryness after two weeks, supporting AbbVie’s aesthetics and consumer-health growth strategy. SkinMedica Adds Barrier Calming Cream
• Positive Sentiment: AbbVie is cited as a potential beneficiary of an aging population, with its immunology portfolio positioned to capture long-term healthcare demand. Aging Population Drives Healthcare Growth
• Neutral Sentiment: AbbVie will present at the Wells Fargo Healthcare Conference on September 9. The event could provide updates on its pipeline, Humira replacement products and financial outlook, but no new information was announced yet. AbbVie Wells Fargo Healthcare Conference
• Neutral Sentiment: Investors are largely waiting for AbbVie’s next earnings update, leaving the stock without a major new near-term catalyst. AbbVie Stock Holds Steady
• Neutral Sentiment: New 340B-related court developments could affect drug-company pricing and reimbursement, but the article does not identify a specific immediate impact on AbbVie. 340B Court Updates
• Negative Sentiment: Erste Group Bank reduced its fiscal 2026 EPS estimate for AbbVie, signaling somewhat more cautious expectations for earnings growth. AbbVie FY2026 EPS Estimates Reduced

Analyst Ratings Changes

Several equities research analysts have issued reports on the stock. Morgan Stanley reiterated an "overweight" rating and set a $296.00 price objective on shares of AbbVie in a research note on Monday, August 3rd. Canaccord Genuity Group raised their target price on shares of AbbVie from $282.00 to $290.00 and gave the company a "buy" rating in a research note on Monday, August 3rd. Wolfe Research upgraded shares of AbbVie from a "peer perform" rating to an "outperform" rating and set a $300.00 target price on the stock in a report on Thursday, August 13th. UBS Group upped their price target on shares of AbbVie from $230.00 to $260.00 and gave the stock a "neutral" rating in a research report on Monday, July 13th. Finally, Wells Fargo & Company increased their price target on AbbVie from $295.00 to $300.00 and gave the company an "overweight" rating in a report on Monday, August 17th. Two analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have assigned a Hold rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $275.95.

Insider Transactions at AbbVie

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the company's stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the transaction, the executive vice president directly owned 74,430 shares of the company's stock, valued at $18,607,500. This represents a 30.53% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 0.06% of the stock is owned by corporate insiders.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source